Showing results (21-30 of 288) with videos related to
Sort By:
Pageof 29
Targeted Oncology|June 17, 2017
Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There YetDaniel P Petrylak, E David CrawfordThe Canadian Journal of Urology|April 30, 2014
Traditional androgen ablation approaches to advanced prostate cancer: new insightsKyle O Rove, E David CrawfordOncology (Williston Park, N.Y.)|February 15, 2012
Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survivalKyle O Rove, E David CrawfordOncology (Williston Park, N.Y.)|March 8, 2012
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approachesE David Crawford, Thomas W FlaigThe Urologic Clinics of North America|May 5, 2004
Screening for prostate cancer: current recommendationsShandra S Wilson, E David CrawfordClinical Prostate Cancer|July 29, 2004
Screening for prostate cancerShandra S Wilson, E David CrawfordReviews in Urology|April 30, 2010
Intermittent androgen deprivation therapy: redefining the standard of care?Neal D Shore, E David CrawfordCurrent Pharmaceutical Design|March 7, 2006
Controversies of androgen ablation therapy for metastatic prostate cancerShandra S Wilson, E David CrawfordCurrent Oncology Reports|April 7, 2004
Artificial neural networks for predictive modeling in prostate cancerEduard J Gamito, E David CrawfordOncology (Williston Park, N.Y.)|January 17, 2015
ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injuryE David Crawford, Judd W MoulPageof 29